While RT aims to damage the cancer cells using precise radiation energy, the use of the aromatase inhibitor is anticipated to effectively target the estrogen-dependent nature of the cancer, whereas the CDK4/6 inhibitor, palbociclib, is expected to reduce the ulceration, bleeding, and skin retraction. This evidence concerns the gene CYP19A1 and cancer.